• OPEN AN ACCOUNT
Indian Indices
Nifty
25,891.40 22.80
(0.09%)
Sensex
84,556.40 130.06
( 0.15%)
Bank Nifty
58,078.05 70.85
( 0.12%)
Nifty IT
36,078.65 778.90
( 2.21%)
Global Indices
Nasdaq
46,757.34 145.93
(0.31%)
Dow Jones
6,759.46 39.06
(0.58%)
Hang Seng
48,675.08 -632.71
(-1.28%)
Nikkei 225
9,578.57 63.57
(0.67%)
Forex
USD-INR
87.98 0.08
(0.09%)
EUR-INR
102.21 -0.23
(-0.23%)
GBP-INR
117.73 -0.22
(-0.19%)
JPY-INR
0.58 0.00
(-0.48%)

EQUITY - MARKET SCREENER

Poddar Pigments Ltd
Industry :  Dyes And Pigments
BSE Code
ISIN Demat
Book Value()
524570
INE371C01013
342.5164939
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
PODDARMENT
15.55
301.32
EPS(TTM)
Face Value()
Div & Yield %
18.26
10
1.41
 

sera investments & finance india ltd
Fredun Pharma gains after launching new product
Oct 13,2025
The product, launched under Fredun's Freossi brand, is free from root vegetables, meat, and animal-derived ingredients, in line with Jain dietary principles. It is designed to support pet immunity, digestion, bone health, and energy.

Snacky Jain will be initially available in six cities through veterinary clinics, online platforms, and retail partners, with expansion planned for Ahmedabad, Pune, Bengaluru, and Delhi.

The product is manufactured at the company’s WHO-GMP-certified Palghar facility. Fredun said the launch strengthens its position in India's pet healthcare market, estimated at Rs 10,000 crore and growing at over 22% annually.

Fredun Pharmaceuticals, a healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

On a standalone basis, Fredun Pharmaceuticals' net profit rose 63.92% to Rs 6.77 crore while net sales rose 53.99% to Rs 119.40 crore in Q1 June 2025 over Q1 June 2024.